Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. (NYSE: A) is a global company in analytical and clinical laboratory technologies, and its news flow reflects activity across life sciences, diagnostics, and applied markets. Company announcements highlight how Agilent’s instruments, software, services, and expertise are used to help customers bring great science to life, as well as how it manages its financial performance and corporate governance.
On this page, readers can follow Agilent news related to earnings results, product introductions, regulatory-focused solutions, capital allocation, and investor events. Recent releases include quarterly and full-year financial results, with details on revenue, net income, and segment performance for the Life Sciences and Diagnostics Markets Group, the Agilent CrossLab Group, and the Applied Markets Group. These updates often include management commentary on business conditions and outlook.
Agilent’s news also covers product and technology developments. For example, the company has announced 21 CFR Part 11 compliance software for the xCELLigence RTCA eSight system, designed to support use in GMP-regulated manufacturing and quality control environments by adding secure user authentication, electronic signatures, and audit trails. Another announcement introduced Agilent Altura Ultra Inert HPLC Columns, described as high performance liquid chromatography columns suited for biotherapeutics applications such as peptide GLP-1 and oligonucleotide therapeutic development and quality control.
Investors and analysts can also find updates on capital markets activities, such as cash dividend declarations on Agilent’s common stock, and notices of participation in healthcare and investor conferences. Governance-related news, including leadership transitions and executive appointments, is communicated through press releases and related SEC filings. Bookmarking this page allows users to review Agilent’s ongoing communications about its operations, technologies, financial performance, and corporate developments in one place.
TORM plc (NASDAQ: TRMD) announced that the threshold date in its articles has occurred on 6 January 2026 after Hafnia's acquisition reduced Oaktree's stake below one-third.
As a result, the B-Director position and related authorities are extinguished, Deputy Chairman David Weinstein leaves the Board effective this date and will continue as Special Advisor. Article 137 limitations cease to have effect immediately. C-share voting rights for 350,000,000 shares have ceased; one B-share retains one vote until redemption. Voting rights now total 101,332,707 A-shares plus one B-share. Post-redemption share capital will be USD 1,013,327.07 divided into 101,332,707 A-shares of USD 0.01 each.
TORM plc (NASDAQ: TRMD / TRMD A) announced that Oaktree completed its acquisition of A shares on 22 December 2025. Following the transaction, Oaktree holds 26,425,059 A shares and Hafnia holds 14,156,061 A shares out of a total 101,332,707 A shares.
The board will now follow Article 5 of the Articles to determine the threshold date when Oaktree and affiliates first ceased to beneficially own at least one third of issued shares. On the threshold date the office of the B director, the C share voting rights and the limitations under Article 137 will cease to have effect, and the B and C share will be redeemed and cancelled. Further announcements will follow once processes conclude.
TORM plc (Nasdaq: TRMD / TRMD A) announced that the Board appointed Simon Mackenzie Smith as Chair of the Board, effective December 16, 2025, succeeding Chris Boehringer.
The change follows a planned succession process and the Board emphasized continuity and long‑term value creation for shareholders. Chris Boehringer, who served as Chair since 2015, will remain a Board member. The release highlights TORM's strengthened financial position and continued development of the One TORM platform during Boehringer's tenure.
Agilent (NYSE: A) announced that CEO Padraig McDonnell and CFO Adam Elinoff will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 13, 2026, 9:00–9:40 a.m. PST. A live audio webcast and replay will be available via Agilent’s investor relations website.
Agilent reported $6.95 billion in revenue for fiscal year 2025 and employs approximately 18,000 people worldwide. The presentation likely will review recent performance and strategic priorities; investors can access the webcast and contact investor relations for more information.
Agilent (NYSE: A) released a 21 CFR Part 11 compliance software upgrade for the xCELLigence RTCA eSight system on December 1, 2025. The software adds a compliance license and enhanced security features—secure user authentication, electronic signatures, and complete audit trails—enabling deployment in GMP-regulated manufacturing and quality control as well as drug discovery labs.
The upgrade is positioned to support continuity from early research to production, improve audit readiness, and simplify regulatory submissions while maintaining workflow efficiency and data quality.
Agilent (NYSE: A) reported Q4 FY2025 revenue $1.86B, up 9.4% reported and up 7.2% on a core basis versus Q4 2024, with GAAP EPS of $1.53 (up 25% YoY) and non-GAAP EPS of $1.59 (up 9% YoY). Full FY2025 revenue was $6.95B, up 6.7% reported; FY2025 GAAP EPS was $4.57 and non-GAAP EPS was $5.59. Management provided FY2026 guidance of $7.3B–$7.4B revenue (up 5%–7% reported) and non-GAAP EPS $5.86–$6.00; Q1 FY2026 revenue guidance is $1.79B–$1.82B with non-GAAP EPS $1.35–$1.38.
Crawford & Company (NYSE: CRD-A and CRD-B) announced a leadership transition: CEO Rohit Verma will step down effective December 31, 2025, and CFO W. Bruce Swain Jr. will become interim president & CEO and board member effective January 1, 2026. Holly Boudreau will succeed Swain as CFO effective January 1, 2026. Swain brings more than 30 years at Crawford and will focus on executing strategic plans and empowering employees. Verma served as CEO since May 2020 and joined Crawford in 2017. The company describes the transition as occurring from a position of financial strength with a global leadership team in place.
Agilent (NYSE: A) announced a quarterly cash dividend of 25.5 cents per share. The dividend is payable on Jan. 28, 2026 to shareholders of record at the close of business on Jan. 6, 2026. The company said timing and amounts of future dividends remain subject to the board of directors’ determination and approval.
Agilent reported $6.51 billion in revenue for fiscal year 2024 and employs approximately 18,000 people worldwide. The release includes customary forward-looking statement language about risks and uncertainties related to the dividend program.
Agilent Technologies (NYSE: A) announced the Altura Ultra Inert HPLC columns, a new product line aimed at biotherapeutics analysis including peptide GLP-1 and oligonucleotide workflows. The release highlights faster conditioning, improved peak shape, enhanced sensitivity, and a fully inert sample flow path designed for demanding QC and development labs.
Agilent claims up to 2x sensitivity, 3x signal-to-noise ratio, and, when paired with the Agilent 1290 Infinity III Bio LC, up to 30x higher peak area; an external test cited a ~30% sensitivity increase and reduced peak tailing on acidic peptides.
Agilent (NYSE: A) will participate in Citi’s 2025 Global Healthcare Conference on Dec. 4, 2025. Chief Enterprise Transformation Officer Tom Callihan and Head of Investor Relations Tejas Savant will take part in a fireside chat from 9:00 to 9:45 a.m. EDT in Miami.
A live audio webcast and replay will be available on Agilent’s investor relations website. Agilent reported $6.51 billion revenue in fiscal year 2024 and employs approximately 18,000 people worldwide.
FAQ
What is the current stock price of Agilent Technologies (A)?
What is the market cap of Agilent Technologies (A)?
